Home > Insider Trading > Filing (0001019056-13-000061)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1338042	Aegerion Pharmaceuticals Inc.	AEGR	Pharmaceutical Preparations (2834)	202960116

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1164426	Joseph Edelman	Perceptive Advisors Llc 499 Park Avenue, 25Th Floor New York NY 10022	No	No	Yes	No
1224962	Perceptive Advisors Llc	499 Park Avenue 25Th Floor New York NY 10022	No	No	Yes	No
1249675	Ltd Fund Master Sciences Life Perceptive	C/O Perceptive Advisors Llc 499 Park Avenue, 25Th Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-01-11	125,000	$26.64	2,873,426	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2013-01-11	200,000	$27.66	3,073,426	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2013-01-11	150,000	$26.64	3,223,426	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Footnotes

This Form 4 is being filed by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"), Perceptive Advisors LLC (the "Advisor") and Joseph Edelman. The Advisor serves as investment manager to the Master Fund. Mr. Edelman is the managing member of the Advisor.
Effective January 1, 2013, the Advisor assumed sole investment discretion over a managed account (the "Managed Account") pursuant to a discretionary managed account agreement between the Advisor and BioEdelman LLC, an entity indirectly owned by Mr. Edelman. At such time, the Managed Account held 133,133 shares of common stock of the Issuer. These transactions reflect the purchase of securities by the Advisor and are held in the Managed Account.
This amount reflects the total amount of securities held by the Master Fund and the Managed Account immediately following the transaction requiring the filing of this statement. In accordance with Instruction 5(b)(iv) of Form 4, the entire amount of the Issuer's securities held by the Master Fund and the Managed Account is reported herein. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.